Img_1516.jpg_thumb90

María Ignacia Fuentes Bustos

Research Director / Associate Professor

Fundación DEBRA Chile / Universidad del Desarrollo

Saltiago, Chile

Líneas de Investigación


Genetics, Molecular Biology, Skin Research and Wound healing, Epidermolysis Bullosa, Horizontal Gene Transfer, New technologies, FACS and Omics. FONDECYT Initiation into Research 11140440 (2014-2017) FONDECYT Regular 1181093 (2018-2021)

Educación

  •  Ph.D., Potsdam University and Max Planck Institute for Molecular Plant Physiology. Alemania, 2012
  •  Biochemistry, Pontificia Universidad Católica de Chile. Chile, 2007
  •  Research in Dermatology, JEFFERSON UNIVERSITY. Estados Unidos, 2019
  •  Molecular Biology and Genetics , MAX-PLANCK INSTITUT FUR MOLEKULARE PFLANZENPHYSIOLOGIE. Alemania, 2013

Experiencia Profesional

  •   Associated Researcher

    Centro de Biotecnología Vegetal UNAB

    Santiago, Chile

    2007 - 2008

  •   Researcher Full Time

    Fundación DEBRA Chile

    Chile

    2013 - 2017

  •   Research Director Part Time

    Fundación DEBRA Chile

    Chile

    2017 - A la fecha

  •   Independent Researcher Part Time

    Universidad del Desarrollo

    Chile

    2013 - 2019

  •   Associate Professor Part Time

    Universidad del Desarrollo, ICIM CGG

    Chile

    2020 - A la fecha

Formación de Capital Humano


Students from undergraduate and postgraduate degrees:
-Biology, PUC
-Medical Technologist, U Mayor
-Biotechnology U Mayor
-Odontology, U de Chile
-Master, U de Valparaíso
-PhD, Biological Sciences PUC


Premios y Distinciones

  •   Jeff Schell prize

    MAX-PLANCK INSTITUT FUR MOLEKULARE PFLANZENPHYSIOLOGIE

    Alemania, 2013

    Awarded to one Ph.D. student per year for outstanding scientific work

  •   IMPRS (International Max Planck Research School) fellowship

    MAX-PLANCK INSTITUT FUR MOLEKULARE PFLANZENPHYSIOLOGIE

    Alemania, 2008

    Complete Fellowship to do the doctoral training


 

Article (16)

Clinical Practice Guidelines for Epidermolysis Bullosa Laboratory Diagnosis.
Epidermolysis Bullosa Simplex with KLHL24 Mutations Is Associated with Dilated Cardiomyopathy
Epidermolysis bullosa simplex-generalized severe type due to keratin 5 p.Glu477Lys mutation=> Genotype-phenotype correlation and in silico modeling analysis.
Epithelial HMGB1 Delays Skin Wound Healing andDrives Tumor Initiation by Priming Neutrophils for NET Formation.
Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
Reduced Microbial Diversity Is a Feature of Recessive Dystrophic Epidermolysis Bullosa-Involved Skin and Wounds
Molecular epidemiology of junctional epidermolysis bullosa: discovery of novel and frequent LAMB3 mutations in Chilean patients with diagnostic significance
Molecular epidemiology of junctional epidermolysis bullosa=> discovery of novel and frequent LAMB3 mutations in Chilean patients with diagnostic significance.
Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy.
Horizontal genome transfer as an asexual path to the formation of new species
Experimental Reconstruction of the Functional Transfer of Intron- Containing Plastid Genes to the Nucleus
A Nuclear Gene Encoding the Iron-Sulfur Subunit of Mitochondrial Complex II Is Regulated by B3 Domain Transcription Factors during Seed Development in Arabidopsis

Proyecto (5)

INVESTIGATING THE ROLE OF SKIN MICROBIOME, HOST IMMUNITY AND INFECTION IN EPIDERMOLYSIS BULLOSA WOUND HEALING
Caracterización genética de pacientes chilenos con Epidermolisis Bulosa de la Unión=> búsqueda de mutaciones frecuentes y desarrollo de un test rápido de diagnóstico.
Desarrollo de una novedosa plataforma tecnológica para diagnosticar enfermedades genéticas=> uso de Epidermolisis Bulosa como prueba de concepto.
DETERMINING THE GENETIC BASIS OF EPIDERMOLYSIS BULLOSA SYMPTOMS THROUGH GENOTYPE-PHENOTYPE ASSOCIATIONS USING NEXT GENERATION SEQUENCING
Implementación del método de inmunofluorescencia para EB=> Posicionando a Chile como foco regional en diagnóstico de EB.
9
María Fuentes

Research Director / Associate Professor

Fundación DEBRA Chile / Universidad del Desarrollo

Saltiago, Chile

2
Maria Holuigue

Profesor Titular

Departamento de Genética Molecular y Microbiología

FACULTAD DE CIENCIAS BIOLÓGICAS, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

2
Xavier Jordana

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE

Santiago, Chile

1
Hannetz Roschzttardtz

Profesor asistente

Genética Molecular y Microbiología

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Boris Rebolledo

Researcher

Center for Genetics and Genomics

Universidad del Desarrollo

Santiago, Chile

1
Hannetz Roschzttardtz

Profesor asistente

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Santiago, Chile